Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in Subjects with Type 2 Diabetes

Study identifier:H8O-MC-GWDE

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in Subjects with Type 2 Diabetes and Inadequate Glycemic Control Treated with Lifestyle Modification and Oral Antidiabetic Medications

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 3

Healthy volunteers

No

Study drug

exenatide once weekly, liraglutide

Sex

All

Actual Enrollment

912

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jan 2010
Primary Completion Date: 01 Jan 2011
Study Completion Date: 01 Apr 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria